Related Experiment Video
Updated: Feb 14, 2026

Assessing Cellular Target Engagement by SHP2 PTPN11 Phosphatase Inhibitors
Published on: July 17, 2020
Differential Effector Engagement by Oncogenic KRAS
Tina L Yuan1, Arnaud Amzallag2, Rachel Bagni3
1Helen Diller Family Comprehensive Cancer Center, University of California, San Francisco, 1450 3rd Street, San Francisco, CA 94158, USA.
Abstract:
KRAS can bind numerous effector proteins, which activate different downstream signaling events. The best known are RAF, phosphatidylinositide (PI)-3' kinase, and RalGDS families, but many additional direct and indirect effectors have been reported. We have assessed how these effectors contribute to several major phenotypes in a quantitative way, using an arrayed combinatorial siRNA screen in which we knocked down 41 KRAS effectors nodes in 92 cell lines. We show that every cell line has a unique combination of effector dependencies, but in spite of this heterogeneity, we were able to identify two major subtypes of KRAS mutant cancers of the lung, pancreas, and large intestine, which reflect different KRAS effector engagement and opportunities for therapeutic intervention.
Insights
This study reveals distinct KRAS effector dependencies in cancer cell lines. Identifying two subtypes of KRAS-mutant cancers offers new therapeutic strategies.
Area of Science:
- Oncology
- Molecular Biology
- Genetics
Background:
- KRAS is a key oncogene in various cancers, activating diverse downstream signaling pathways through effector proteins.
- Understanding KRAS effector interactions is crucial for developing targeted cancer therapies.
Purpose of the Study:
- To quantitatively assess the contribution of KRAS effectors to cancer phenotypes.
- To identify distinct patterns of KRAS effector engagement in KRAS-mutant cancers.
- To explore potential therapeutic interventions based on identified effector dependencies.
Main Methods:
- Utilized an arrayed combinatorial siRNA screen targeting 41 KRAS effector nodes.
- Analyzed 92 cancer cell lines across lung, pancreas, and large intestine.
- Quantitatively assessed effector contributions to major cancer phenotypes.
Main Results:
- Demonstrated unique combinations of effector dependencies across all cell lines.
- Identified two major subtypes of KRAS-mutant cancers based on effector engagement.
- Highlighted heterogeneity in KRAS effector networks.
Conclusions:
- KRAS-mutant cancers exhibit distinct effector engagement profiles, defining subtypes.
- These subtypes represent different therapeutic vulnerabilities and opportunities.
- Further research into KRAS effector pathways can guide precision oncology strategies.
Related Concept Videos
Cancer-Critical Genes I: Proto-oncogenes
When the function of certain critical genes, especially those involved in cell cycle regulation and cell growth signaling cascades, gets disrupted, it upsets the cell cycle progression. Such cells with unchecked cell cycles start proliferating uncontrollably and eventually develop into tumors.
Such genes that act...
Implicit Differentiation
Logarithmic Differentiation
Cellular Differentiation
A zygote is a...
Differential Leveling
Integrator and Differentiator
An integrator within an op-amp circuit produces an output directly proportional to the integral of the input signal. This is achieved by replacing the feedback resistor in a typical inverting...

